NASDAQ:NGNE

Neurogene (NGNE) Stock Price, News & Analysis

Neurogene logo
$23.10 -0.20 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$22.52 -0.58 (-2.53%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Neurogene Stock (NASDAQ:NGNE)

Advanced

Key Stats

Today's Range
$22.21
▼
$23.38
50-Day Range
$21.56
▼
$37.88
52-Week Range
$15.93
▼
$43.66
Volume
278,143 shs
Average Volume
294,110 shs
Market Capitalization
$478.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.57
Consensus Rating
Buy

Company Overview

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options.

The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

Founded in 2018, Neurogene is based in the United States and is led by founder and Chief Executive Officer Rachel McMinn.

AI Generated. May Contain Errors.

Neurogene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

NGNE MarketRank™: 
2.35415009281 of 5 stars

Neurogene scored higher than 47% of companies evaluated by MarketBeat, and ranked 574th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Neurogene has a consensus price target of $79.57, representing about 244.5% upside from its current price of $23.10.

  • Amount of Analyst Coverage

    Neurogene has only been the subject of 4 research reports in the past 90 days.

  • Read more about Neurogene's stock forecast and price target.
  • Earnings Growth

    Earnings for Neurogene are expected to decrease in the coming year, from ($5.26) to ($5.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Neurogene is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Neurogene is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Neurogene has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    32.17% of the float of Neurogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Neurogene has a short interest ratio ("days to cover") of 16.95, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Neurogene has recently increased by 11.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Neurogene does not currently pay a dividend.

  • Dividend Growth

    Neurogene does not have a long track record of dividend growth.

  • News Sentiment

    Neurogene has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Neurogene this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for NGNE on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neurogene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.68% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Neurogene's insider trading history.
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NGNE Stock News Headlines

Neurogene FY2026 Earnings Forecast Raised by HC Wainwright
Canaccord Genuity Keeps Their Buy Rating on Neurogene (NGNE)
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Neurogene to Participate in Upcoming Investor Conferences
See More Headlines

NGNE Stock Analysis - Frequently Asked Questions

Neurogene's stock was trading at $20.60 at the start of the year. Since then, NGNE stock has increased by 12.1% and is now trading at $23.10.

Neurogene Inc. (NASDAQ:NGNE) released its earnings results on Monday, November, 9th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.31.

Neurogene (NGNE) raised $46 million in an IPO on Thursday, March 6th 2014. The company issued 4,200,000 shares at $10.00-$12.00 per share.

Top institutional shareholders of Neurogene include Samsara Biocapital LLC (9.02%), State Street Corp (2.65%), Great Point Partners LLC (1.45%) and Integral Health Asset Management LLC (0.97%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb.
View institutional ownership trends
.

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/09/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
CIK
1404644
Employees
131
Year Founded
2018

Price Target and Rating

High Price Target
$166.00
Low Price Target
$50.00
Potential Upside/Downside
+244.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$90.35 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.36%
Return on Assets
-40.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.97
Quick Ratio
10.64

Sales & Book Value

Annual Sales
$930 thousand
Price / Sales
514.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$17.14 per share
Price / Book
1.35

Miscellaneous

Outstanding Shares
20,700,000
Free Float
18,283,000
Market Cap
$478.17 million
Optionable
Optionable
Beta
1.75

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:NGNE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners